These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 24974831

  • 1. Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth.
    Jung SK, Lee MH, Lim DY, Lee SY, Jeong CH, Kim JE, Lim TG, Chen H, Bode AM, Lee HJ, Lee KW, Dong Z.
    Mol Carcinog; 2015 Apr; 54(4):322-31. PubMed ID: 24974831
    [Abstract] [Full Text] [Related]

  • 2. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
    Oh HN, Lee MH, Kim E, Yoon G, Chae JI, Shim JH.
    Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
    [Abstract] [Full Text] [Related]

  • 3. Targeted inhibition of c-MET by podophyllotoxin promotes caspase-dependent apoptosis and suppresses cell growth in gefitinib-resistant non-small cell lung cancer cells.
    Oh HN, Kwak AW, Lee MH, Kim E, Yoon G, Cho SS, Liu K, Chae JI, Shim JH.
    Phytomedicine; 2021 Jan; 80():153355. PubMed ID: 33039730
    [Abstract] [Full Text] [Related]

  • 4. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
    Zhou JY, Chen X, Zhao J, Bao Z, Chen X, Zhang P, Liu ZF, Zhou JY.
    Cancer Lett; 2014 Sep 01; 351(2):265-71. PubMed ID: 24983493
    [Abstract] [Full Text] [Related]

  • 5. TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
    Wu DW, Chen TC, Huang HS, Lee H.
    Cell Death Dis; 2016 Jun 30; 7(6):e2290. PubMed ID: 27362807
    [Abstract] [Full Text] [Related]

  • 6. Dual inhibition of EGFR and MET by Echinatin retards cell growth and induces apoptosis of lung cancer cells sensitive or resistant to gefitinib.
    Oh HN, Lee MH, Kim E, Kwak AW, Seo JH, Yoon G, Cho SS, Choi JS, Lee SM, Seo KS, Chae JI, Shim JH.
    Phytother Res; 2020 Feb 30; 34(2):388-400. PubMed ID: 31698509
    [Abstract] [Full Text] [Related]

  • 7. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.
    Clin Cancer Res; 2009 Feb 01; 15(3):907-13. PubMed ID: 19188161
    [Abstract] [Full Text] [Related]

  • 8. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A.
    Mol Cancer Res; 2010 Aug 01; 8(8):1142-51. PubMed ID: 20647329
    [Abstract] [Full Text] [Related]

  • 9. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
    Chen X, Zhou JY, Zhao J, Chen JJ, Ma SN, Zhou JY.
    Anticancer Drugs; 2013 Nov 01; 24(10):1039-46. PubMed ID: 23962905
    [Abstract] [Full Text] [Related]

  • 10. Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification.
    Jang WJ, Jung SK, Kang JS, Jeong JW, Bae MK, Joo SH, Park GH, Kundu JK, Hong YS, Jeong CH.
    Cancer Sci; 2014 Oct 01; 105(10):1245-53. PubMed ID: 25117641
    [Abstract] [Full Text] [Related]

  • 11. Licochalcone D Induces ROS-Dependent Apoptosis in Gefitinib-Sensitive or Resistant Lung Cancer Cells by Targeting EGFR and MET.
    Oh HN, Lee MH, Kim E, Kwak AW, Yoon G, Cho SS, Liu K, Chae JI, Shim JH.
    Biomolecules; 2020 Feb 13; 10(2):. PubMed ID: 32070026
    [Abstract] [Full Text] [Related]

  • 12. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y, Yao K, Shi C, Jiang Y, Liu K, Zhao S, Chen H, Reddy K, Zhang C, Chang X, Ryu J, Bode AM, Dong Z, Dong Z.
    Oncotarget; 2015 Dec 29; 6(42):44274-88. PubMed ID: 26517520
    [Abstract] [Full Text] [Related]

  • 13. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M, He CS, Wei SH, Zhang L.
    Eur J Cancer; 2013 Nov 29; 49(16):3559-72. PubMed ID: 23916913
    [Abstract] [Full Text] [Related]

  • 14. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M, Xia S, Zhuang L, Han N, Chu Q, Chao T, Peng P, Chen Y, Gui Q, Yu S.
    Int J Oncol; 2013 Jun 29; 42(6):2094-102. PubMed ID: 23588221
    [Abstract] [Full Text] [Related]

  • 15. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M, Yuan Y, Pan YY, Zhang Y.
    Mol Med Rep; 2014 Jun 29; 9(6):2417-22. PubMed ID: 24682085
    [Abstract] [Full Text] [Related]

  • 16. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.
    Crit Rev Oncol Hematol; 2014 Feb 29; 89(2):284-99. PubMed ID: 24355409
    [Abstract] [Full Text] [Related]

  • 17. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
    Han SY, Zhao MB, Zhuang GB, Li PP.
    Lung Cancer; 2012 Jan 29; 75(1):30-7. PubMed ID: 21757251
    [Abstract] [Full Text] [Related]

  • 18. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
    Wu H, Fan F, Liu Z, Shen C, Wang A, Lu Y.
    Cancer Chemother Pharmacol; 2015 Aug 29; 76(2):307-15. PubMed ID: 26063323
    [Abstract] [Full Text] [Related]

  • 19. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
    Hwang KE, Kwon SJ, Kim YS, Park DS, Kim BR, Yoon KH, Jeong ET, Kim HR.
    Exp Cell Res; 2014 May 01; 323(2):288-96. PubMed ID: 24631288
    [Abstract] [Full Text] [Related]

  • 20. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
    Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S.
    Clin Cancer Res; 2011 Apr 15; 17(8):2260-9. PubMed ID: 21220474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.